https://www.selleckchem.com/products/ff-10101.html
64; 95% confidence interval [CI], 0.51-0.80; p0.001) and HCC-related death (HR, 0.52; 95% CI, 0.36-0.76; p=0.001) compared to that with NsA therapy. Subgroup analysis showed that TDF treatment was associated with significantly lower rates of HCC recurrence (HR, 0.64; 95% CI, 0.49-0.83; p=0.001) and death (HR, 0.32; 95% CI, 0.20-0.50; p0.001) than ETV treatment. Nucleotide analog treatment, but not NsA treatment, significantly reduced the risk of HCC recurrence in patients with HBV-related HCC and improved overall survival after
Like
Comment
Share
